Simplex Trading Adds $1M in AbCellera Biologics Inc. ($ABCL)
Key Points
- Wall Street's consensus rating on $ABCL is Strong Buy and an average price target of $10.43.
- $ABCL last traded around $5.34.
Simplex Trading acquired a new position in AbCellera Biologics Inc. ($ABCL), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 201,236 shares of AbCellera Biologics Inc.. Simplex Trading's holdings in AbCellera Biologics Inc. were worth $1.07 million as of its most recent filing.
AbCellera Biologics Inc. ($ABCL) Stock
AbCellera Biologics Inc. Earnings
Analysts Set New Price Targets
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.